Described is a composition comprising a synergistic combination of a tyrosine kinase inhibitor and a chemical castration agent. The tyrosine kinase inhibitor is selected from a trkA inhibitor a trkB inhibitor a trkC inhibitor or an indolocarbazole. The chemical castration agents include oestrogens; LHRH agonists e.g. leuprolide acetate (LUPRON®) and goserelin acetate (ZOLADEX®); LHRH antagonists e.g. ANTIDE® (Ares-Serono) and GANIRELIX® (Akzo Nobel); and antiandrogens e.g. flutamide and nilutami...

Described is a composition comprising a synergistic combination of a tyrosine kinase inhibitor and a chemical castration agent. The tyrosine kinase inhibitor is selected from a trkA inhibitor a trkB inhibitor a trkC inhibitor or an indolocarbazole. Chemical castration agents include oestrogens; LHRH agonists e.g. leuprolide acetate (LUPRON) and goserelin acetate (ZOLADEX); LHRH antagonists e.g. ANTIDEs (Ares-Serono) and GANIRELIXe (Akzo Nobel); and antiandrogens e.g. flutamide and nilutamide.